Mounjaro long-term side effects: what the evidence actually shows

What SURMOUNT-1 and ongoing monitoring actually found

The pivotal trial (SURMOUNT-1, published in the New England Journal of Medicine) followed 2,539 adults with obesity for 72 weeks. The side-effect picture that emerged was dominated by gastrointestinal events: nausea, vomiting, diarrhoea, constipation and indigestion. Most participants who experienced these reported them in the early weeks, particularly around each dose step, after which they became less frequent. Discontinuation due to side effects ran at around 4–7% across the dose groups, which is broadly in line with other medicines in this class.

Crucially, no pattern of cumulative organ damage appeared across the trial period. Liver enzymes, kidney function markers and cardiovascular parameters were tracked throughout, and no dose-dependent deterioration was observed at the licensed weight-management doses. That said, 72 weeks is not 10 years. Regulators are candid about this: the Black Triangle (▼) on Mounjaro's UK label is precisely how the MHRA signals that post-market surveillance is ongoing and that healthcare professionals and patients should continue reporting anything unexpected. You can read more about the full side-effect profile on our Mounjaro side effects overview.

For a practical sense of what the early weeks feel like for most people, the timeline of how long Mounjaro side effects last is worth reading alongside this page.

The signals regulators are watching most closely

Two areas attract the most regulatory attention for GLP-1 and dual GIP/GLP-1 medicines as a class: pancreatitis and thyroid effects. On pancreatitis, the MHRA's January 2026 Drug Safety Update confirmed it as a known but infrequent risk. The practical upshot: any severe stomach pain that persists and radiates toward the back (with or without vomiting) is a reason to stop the medicine and go to A&E or call 999, not to wait for it to pass. This symptom pattern is distinct from ordinary GI discomfort, which is dull, nausea-led and settles.

On thyroid effects: in rodent studies, semaglutide and tirzepatide at very high doses produced thyroid C-cell changes. This has not been replicated in human data, but it is why Mounjaro is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Your prescriber will ask about this. People without that history are not considered to carry elevated thyroid risk at licensed doses, the Mounjaro SmPC on the eMC sets out the current contraindication wording clearly if you want to read the exact regulatory language.

Gallbladder-related events (including gallstones) have also appeared at slightly higher rates in GLP-1 trials than in placebo groups, attributed partly to rapid weight loss itself rather than the medicine specifically. Sudden right-sided or upper abdominal pain is another symptom that warrants prompt medical review, not watchful waiting.

Side effects that tend to be genuinely long-lasting versus those that resolve

It helps to separate what the evidence says resolves from what can persist. GI symptoms (nausea especially) overwhelmingly fall into the resolving category. Most people find the first two to four weeks of each dose step uncomfortable, and then tolerable. If nausea is still significant at week eight of a given dose, that is a conversation to have with the prescribing team, not something to push through alone.

Fatigue is another early-stage companion for some people, often tied to reduced caloric intake rather than a direct pharmacological effect. A quick daily check worth building in: note whether fatigue is improving week on week. If it is not, and if it comes alongside dizziness or reduced urine output, dehydration from GI side effects is a real possibility, and your prescriber or our aftercare team should hear about it. The page on tiredness on Mounjaro covers this in more detail.

Hair thinning (telogen effluvium) sometimes occurs with significant rapid weight loss of any cause. It is temporary, linked to the metabolic shift rather than tirzepatide itself, and typically reverses as weight stabilises. If you are wondering whether tirzepatide has side effects that differ from those seen in shorter trials, our page on what the long-term side effects of Mounjaro are looks at the current evidence in detail. Injection-site reactions (redness, itching, small lumps) are worth reporting but rarely persist if injection sites are rotated systematically across the abdomen, thigh and upper arm.

When to get medical help, and how to report

Some symptoms should not wait for a scheduled review. Go to A&E or call 999 for: severe persistent stomach pain spreading to the back (pancreatitis); signs of a serious allergic reaction (face, throat or tongue swelling, difficulty breathing); chest pain or shortness of breath. Call 111 or contact your prescriber promptly for: jaundice or right-upper-quadrant pain (gallbladder); significant dehydration you cannot manage orally; low mood or any thoughts of self-harm. If you want a complete picture of what to watch for across all dose levels, our page on what side effects Mounjaro has covers these thresholds in a fuller clinical context.

The MHRA's Yellow Card scheme exists so that patients, not just clinicians, can report suspected side effects directly. Every report filed strengthens the post-market safety database for a medicine that is, by the MHRA's own classification, still under enhanced surveillance. If something feels off, reporting it is genuinely useful, not just for you, but for everyone on the medicine.

At nume (at nume) a GPhC-registered prescriber reviews your case before treatment starts and again at every repeat. Side effects, tolerability and any new symptoms are part of that review, not an afterthought. If you want to talk through whether the benefit-risk balance makes sense for you, our prescribers discuss exactly this as part of the free consultation, start yours here.